Have a personal or library account? Click to login
Statins as Pleiotropic Modifiers of Vascular Oxidative Stress and Inflammation Cover

Statins as Pleiotropic Modifiers of Vascular Oxidative Stress and Inflammation

The Journal of Critical Care Medicine
Volume 1 (2015): Issue 2 (April 2015)
By: Costas Psarros,  Evangelos K. Economou,  Michael Koutsilieris and  Charalambos Antoniades  
Open Access
|Jun 2015

References

  1. 1. Lee R, Margaritis M, Channon KM, et al. Evaluating oxidative stress in human cardiovascular disease: methodological aspects and considerations. Curr Med Chem. 2012;19:2504-20.10.2174/092986712800493057341220422489713
    Search in Google Scholar
  2. 2. Tousoulis D, Psarros C, Demosthenous M, et al. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J Am Coll Cardiol. 2014;63:2491-502.10.1016/j.jacc.2014.01.05424613322
    Search in Google Scholar
  3. 3. Psarros C, Lee R, Margaritis M, et al. Nanomedicine for the prevention, treatment and imaging of atherosclerosis. Nanomedicine. 2012;8 Suppl 1:S59-68.10.1016/j.nano.2012.05.00622640906
    Search in Google Scholar
  4. 4. Antoniades C, Antonopoulos AS, Tousoulis D, et al. Adiponectin: from obesity to cardiovascular disease. Obes Rev. 2009;10:269-79.10.1111/j.1467-789X.2009.00571.x19389061
    Search in Google Scholar
  5. 5. Antonopoulos AS, Lee R, Margaritis M, et al. Adiponectin as a regulator of vascular redox state: therapeutic implications. Recent Pat Cardiovasc Drug Discov. 2011;6:78-88.10.2174/15748901179593383721453253
    Search in Google Scholar
  6. 6. Margaritis M, Antonopoulos AS, Digby J, et al. Interactions between vascular wall and perivascular adipose tissue reveal novel roles for adiponectin in the regulation of endothelial nitric oxide synthase function in human vessels. Circulation. 2013;127:2209-21.10.1161/CIRCULATIONAHA.112.00113323625959
    Search in Google Scholar
  7. 7. Antonopoulos AS, Margaritis M, Coutinho P, et al. Adiponectin As A Link Between Type 2 Diabetes Mellitus And Vascular NADPH-Oxidase Activity In The Human Arterial Wall: The Regulatory Role Of Perivascular Adipose Tissue. Diabetes. 2014. doi: 10.2337/db14-1011 [Epub ahead of print]10.2337/db14-101125552596
    Search in Google Scholar
  8. 8. Channon KM and Guzik TJ. Mechanisms of superoxide production in human blood vessels: relationship to endothelial dysfunction, clinical and genetic risk factors. J Physiol Pharmacol. 2002;53:515-24.
    Search in Google Scholar
  9. 9. Alp NJ, Mussa S, Khoo J, et al. Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J Clin Invest. 2003;112:725-35.10.1172/JCI1778618219612952921
    Search in Google Scholar
  10. 10. Cunnington C, Van Assche T, Shirodaria C, et al. Systemic and Vascular Oxidation Limits the Efficacy of Oral Tetrahydrobiopterin Treatment in Patients With Coronary Artery Disease. Circulation. 2012;125:1356-66.10.1161/CIRCULATIONAHA.111.038919523893522315282
    Search in Google Scholar
  11. 11. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation. 2004;109:II27-33.10.1161/01.CIR.0000129501.88485.1f15173060
    Search in Google Scholar
  12. 12. Antoniades C, Tousoulis D, Vasiliadou C, et al. Genetic polymorphism on endothelial nitric oxide synthase affects endothelial activation and inflammatory response during the acute phase of myocardial infarction. J Am Coll Cardiol. 2005;46:1101-9.10.1016/j.jacc.2005.05.072
    Search in Google Scholar
  13. 13. Antoniades C, Shirodaria C, Warrick N, et al. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation. 2006;114:1193-201.10.1161/CIRCULATIONAHA.106.612325
    Search in Google Scholar
  14. 14. Antoniades C, Shirodaria C, Leeson P, et al. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. Eur Heart J. 2009;30:1142-50.10.1093/eurheartj/ehp061
    Search in Google Scholar
  15. 15. Gounari P, Tousoulis D, Antoniades C, et al. Rosuvastatin but not ezetimibe improves endothelial function in patients with heart failure, by mechanisms independent of lipid lowering. Int J Cardiol. 2010;142:87-91.10.1016/j.ijcard.2008.12.067
    Search in Google Scholar
  16. 16. Antoniades C, Demosthenous M, Tousoulis D, et al. Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis. Hypertension. 2011;58:93-8.10.1161/HYPERTENSIONAHA.110.168245
    Search in Google Scholar
  17. 17. Ait-Oufella H, Taleb S, Mallat Z, et al. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31:969-79.10.1161/ATVBAHA.110.207415
    Search in Google Scholar
  18. 18. Tousoulis D, Antoniades C, Stefanadis C. Assessing inflammatory status in cardiovascular disease. Heart. 2007;93:1001-7.10.1136/hrt.2006.088211
    Search in Google Scholar
  19. 19. Kim JH, Bachmann RA, Chen J. Interleukin-6 and insulin resistance. Vitam Horm. 2009;80:613-33.10.1016/S0083-6729(08)00621-3
    Search in Google Scholar
  20. 20. Schuett H, Luchtefeld M, Grothusen C, et al. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost. 2009;102:215-22.10.1160/TH09-05-029719652871
    Search in Google Scholar
  21. 21. Abeywardena MY, Leifert WR, Warnes KE, et al. Cardiovascular biology of interleukin-6. Curr Pharm Des. 2009;15:1809-21.10.2174/13816120978818629019442192
    Search in Google Scholar
  22. 22. Yudkin JS, Kumari M, Humphries SE, et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000;148:209-14.
    Search in Google Scholar
  23. 23. Hartge MM, Unger T, Kintscher U. The endothelium and vascular inflammation in diabetes. Diab Vasc Dis Res. 2007;4:84-8.10.3132/dvdr.2007.025
    Search in Google Scholar
  24. 24. Wang Z, Castresana MR, Newman WH. Reactive oxygen and NFkappaB in VEGF-induced migration of human vascular smooth muscle cells. Biochem Biophys Res Commun. 2001;285:669-74.10.1006/bbrc.2001.5232
    Search in Google Scholar
  25. 25. Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008;4:34-42.10.1038/ncprheum0681
    Search in Google Scholar
  26. 26. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479-90.10.1016/j.immuni.2005.09.015
    Search in Google Scholar
  27. 27. Okamura H, Tsutsui H, Kashiwamura S, et al. Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol. 1998;70:281-312.10.1016/S0065-2776(08)60389-2
    Search in Google Scholar
  28. 28. Pizarro TT, Cominelli F. Cloning IL-1 and the birth of a new era in cytokine biology. J Immunol. 2007;178:5411-2.10.4049/jimmunol.178.9.541117442919
    Search in Google Scholar
  29. 29. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy--review of a new approach. Pharmacol Rev. 2003;55:241-69.10.1124/pr.55.2.412773629
    Search in Google Scholar
  30. 30. Han X, Kitamoto S, Wang H, et al. Interleukin-10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice. FASEB J. 2010;24:2869-80.10.1096/fj.09-148155290928320354139
    Search in Google Scholar
  31. 31. Han X, Kitamoto S, Lian Q, et al. Interleukin-10 facilitates both cholesterol uptake and efflux in macrophages. J Biol Chem. 2009;284:32950-8.10.1074/jbc.M109.040899278171019776020
    Search in Google Scholar
  32. 32. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol. 2003;73:213-24.10.1189/jlb.060231312554798
    Search in Google Scholar
  33. 33. Blankenberg S, Tiret L, Bickel C, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002;106:24-30.10.1161/01.CIR.0000020546.30940.92
    Search in Google Scholar
  34. 34. Tziakas DN, Chalikias GK, Kaski JC, et al. Inflammatory and anti-inflammatory variable clusters and risk prediction in acute coronary syndrome patients: a factor analysis approach. Atherosclerosis. 2007;193:196-203.10.1016/j.atherosclerosis.2006.06.016
    Search in Google Scholar
  35. 35. Lin S, Lee CK, Wang YM, et al. Measurement of dimensions of pentagonal doughnut-shaped C-reactive protein using an atomic force microscope and a dual polarisation interferometric biosensor. Biosens Bioelectron. 2006;22:323-7.10.1016/j.bios.2006.01.018
    Search in Google Scholar
  36. 36. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation. 2003;108:1930-2. 10.1161/01.CIR.0000096055.62724.C5
    Search in Google Scholar
  37. 37. Venugopal SK, Devaraj S, Jialal I. Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol. 2005;166:1265-71.10.1016/S0002-9440(10)62345-0
    Search in Google Scholar
  38. 38. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805-12.10.1172/JCI200318921
    Search in Google Scholar
  39. 39. Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem. 2001;47:28-30.10.1093/clinchem/47.1.28
    Search in Google Scholar
  40. 40. Elkind MS. Inflammation, atherosclerosis, and stroke. Neurologist. 2006;12:140-8.10.1097/01.nrl.0000215789.70804.b016688015
    Search in Google Scholar
  41. 41. King VL, Thompson J, Tannock LR. Serum amyloid A in atherosclerosis. Curr Opin Lipidol. 2011;22:302-7.10.1097/MOL.0b013e3283488c3921734573
    Search in Google Scholar
  42. 42. Rho YH, Chung CP, Oeser A, et al. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J Rheumatol. 2008;35:1789-94.
    Search in Google Scholar
  43. 43. Min JH, Jain MK, Wilder C, et al. Membrane-bound plasma platelet activating factor acetylhydrolase acts on substrate in the aqueous phase. Biochemistry. 1999;38:12935-42.10.1021/bi991149u10504265
    Search in Google Scholar
  44. 44. Wilensky RL and Macphee CH. Lipoprotein-associated phospholipase A(2) and atherosclerosis. Curr Opin Lipidol. 2009;20:415-20.10.1097/MOL.0b013e3283307c16
    Search in Google Scholar
  45. 45. Anderson JL. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol. 2008;101:23F-33F.10.1016/j.amjcard.2008.04.015
    Search in Google Scholar
  46. 46. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis. 2003;170:191-203.10.1016/S0021-9150(03)00097-2
    Search in Google Scholar
  47. 47. McEver RP. Selectins: lectins that initiate cell adhesion under flow. Curr Opin Cell Biol. 2002;14:581-6.10.1016/S0955-0674(02)00367-8
    Search in Google Scholar
  48. 48. Galkina E, Kadl A, Sanders J, et al. Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J Exp Med. 2006;203:1273-82.10.1084/jem.20052205212120816682495
    Search in Google Scholar
  49. 49. Eriksson EE, Xie X, Werr J, et al. Importance of primary capture and L-selectin-dependent secondary capture in leukocyte accumulation in inflammation and atherosclerosis in vivo. J Exp Med. 2001;194:205-18.10.1084/jem.194.2.205219344911457895
    Search in Google Scholar
  50. 50. Galkina E and Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:2292-301.10.1161/ATVBAHA.107.14917917673705
    Search in Google Scholar
  51. 51. Paez A, Mendez-Cruz AR, Varela E, et al. HUVECs from newborns with a strong family history of myocardial infarction overexpress adhesion molecules and react abnormally to stimulating agents. Clin Exp Immunol. 2005;141:449-58.10.1111/j.1365-2249.2005.02858.x180947016045734
    Search in Google Scholar
  52. 52. Davies MJ, Gordon JL, Gearing AJ, et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol. 1993;171:223-9.10.1002/path.17117103117506307
    Search in Google Scholar
  53. 53. Yu G, Rux AH, Ma P, et al. Endothelial expression of E-selectin is induced by the platelet-specific chemokine platelet factor 4 through LRP in an NF-kappaB-dependent manner. Blood. 2005;105:3545-51.10.1182/blood-2004-07-2617189502415591119
    Search in Google Scholar
  54. 54. Hafezi-Moghadam A, Thomas KL, Prorock AJ, et al. L-selectin shedding regulates leukocyte recruitment. J Exp Med. 2001;193:863-72.10.1084/jem.193.7.863
    Search in Google Scholar
  55. 55. del Pozo MA, Pulido R, Munoz C, et al. Regulation of ICAM-3 (CD50) membrane expression on human neutrophils through a proteolytic shedding mechanism. Eur J Immunol. 1994;24:2586-94.10.1002/eji.1830241104
    Search in Google Scholar
  56. 56. Kostidou E, Topouridou K, Daniilidis A, et al. Oxidized laminin-1 induces increased monocyte attachment and expression of ICAM-1 in endothelial cells. Int J Exp Pathol. 2009;90:630-7.10.1111/j.1365-2613.2009.00686.x
    Search in Google Scholar
  57. 57. Matheny HE, Deem TL, Cook-Mills JM. Lymphocyte migration through monolayers of endothelial cell lines involves VCAM-1 signaling via endothelial cell NADPH oxidase. J Immunol. 2000;164:6550-9.10.4049/jimmunol.164.12.6550
    Search in Google Scholar
  58. 58. Malik I, Danesh J, Whincup P, et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet. 2001;358:971-6.10.1016/S0140-6736(01)06104-9
    Search in Google Scholar
  59. 59. Woodfin A, Voisin MB, Nourshargh S. PECAM-1: a multifunctional molecule in inflammation and vascular biology. Arterioscler Thromb Vasc Biol. 2007;27:2514-23.10.1161/ATVBAHA.107.15145617872453
    Search in Google Scholar
  60. 60. Wong CW, Wiedle G, Ballestrem C, et al. PECAM-1/CD31 transhomophilic binding at the intercellular junctions is independent of its cytoplasmic domain; evidence for heterophilic interaction with integrin alphavbeta3 in Cis. Mol Biol Cell. 2000;11:3109-21.10.1091/mbc.11.9.31091497910982404
    Search in Google Scholar
  61. 61. Mandell KJ, Parkos CA. The JAM family of proteins. Adv Drug Deliv Rev. 2005;57:857-67.10.1016/j.addr.2005.01.00515820556
    Search in Google Scholar
  62. 62. Babinska A, Azari BM, Salifu MO, et al. The F11 receptor (F11R/JAM-A) in atherothrombosis: overexpression of F11R in atherosclerotic plaques. Thromb Haemost. 2007;97:272-81.10.1160/TH06-08-0454
    Search in Google Scholar
  63. 63. Ostermann G, Fraemohs L, Baltus T, et al. Involvement of JAM-A in mononuclear cell recruitment on inflamed or atherosclerotic endothelium: inhibition by soluble JAM-A. Arterioscler Thromb Vasc Biol. 2005;25:729-35.10.1161/01.ATV.0000157154.14474.3b15681301
    Search in Google Scholar
  64. 64. Zernecke A, Liehn EA, Fraemohs L, et al. Importance of junctional adhesion molecule-A for neointimal lesion formation and infiltration in atherosclerosis-prone mice. Arterioscler Thromb Vasc Biol. 2006;26:e10-3.10.1161/01.ATV.0000197852.24529.4f
    Search in Google Scholar
  65. 65. Keiper T, Al-Fakhri N, Chavakis E, et al. The role of junctional adhesion molecule-C (JAM-C) in oxidized LDL-mediated leukocyte recruitment. FASEB J. 2005;19:2078-80.10.1096/fj.05-4196fje
    Search in Google Scholar
  66. 66. Weitz-Schmidt G. Lymphocyte function-associated antigen-1 blockade by statins: molecular basis and biological relevance. Endothelium. 2003;10:43-7.10.1080/10623320303360
    Search in Google Scholar
  67. 67. Welzenbach K, Hommel U, Weitz-Schmidt G. Small molecule inhibitors induce conformational changes in the I domain and the I-like domain of lymphocyte function-associated antigen-1. Molecular insights into integrin inhibition. J Biol Chem. 2002;277:10590-8.10.1074/jbc.M110521200
    Search in Google Scholar
  68. 68. Romano M, Mezzetti A, Marulli C, et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Investig Med. 2000;48:183-9.
    Search in Google Scholar
  69. 69. Seljeflot I, Tonstad S, Hjermann I, et al. Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis. 2002;162:179-85.10.1016/S0021-9150(01)00696-7
    Search in Google Scholar
  70. 70. Rezaie-Majd A, Maca T, Bucek RA, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002;22:1194-9.10.1161/01.ATV.0000022694.16328.CC
    Search in Google Scholar
  71. 71. Izidoro-Toledo TC, Guimaraes DA, Belo VA, et al. Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells. Naunyn Schmiedebergs Arch Pharmacol. 2011;383:547-54.10.1007/s00210-011-0623-0
    Search in Google Scholar
  72. 72. Franzoni F, Quinones-Galvan A, Regoli F, et al. A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol. 2003;90:317-21.10.1016/S0167-5273(02)00577-6
    Search in Google Scholar
  73. 73. Davignon J, Jacob RF, Mason RP. The antioxidant effects of statins. Coron Artery Dis. 2004;15:251-8.10.1097/01.mca.0000131573.31966.3415238821
    Search in Google Scholar
  74. 74. Lim S, Barter P. Antioxidant effects of statins in the management of cardiometabolic disorders. J Atheroscler Thromb. 2014;21:997-1010.10.5551/jat.2439825132378
    Search in Google Scholar
  75. 75. Antoniades C, Bakogiannis C, Tousoulis D, et al. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation. 2010;122:S66-73.10.1161/CIRCULATIONAHA.109.927376
    Search in Google Scholar
  76. 76. Antoniades C, Bakogiannis C, Leeson P, et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterinmediated endothelial nitric oxide synthase coupling. Circulation. 2011;124:335-45.10.1161/CIRCULATIONAHA.110.985150
    Search in Google Scholar
  77. 77. Antonopoulos AS, Margaritis M, Shirodaria C, et al. Translating the effects of statins: from redox regulation to suppression of vascular wall inflammation. Thromb Haemost. 2012;108:840-8.10.1160/TH12-05-0337
    Search in Google Scholar
  78. 78. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307-16.10.1001/jama.292.11.1307
    Search in Google Scholar
  79. 79. Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007.10.1001/jama.288.23.2998
    Search in Google Scholar
  80. 80. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58.10.1016/S0140-6736(03)12948-0
    Search in Google Scholar
  81. 81. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-61.10.1056/NEJMoa0706201
    Search in Google Scholar
  82. 82. Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.10.1016/S0140-6736(02)09327-3
    Search in Google Scholar
  83. 83. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207.10.1056/NEJMoa080764618997196
    Search in Google Scholar
  84. 84. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349-57.
    Search in Google Scholar
  85. 85. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-7. 10.1056/NEJM1995111633320017566020
    Search in Google Scholar
DOI: https://doi.org/10.1515/jccm-2015-0007 | Journal eISSN: 2393-1817 | Journal ISSN: 2393-1809
Journal RSS Feed
Language: English
Page range: 43 - 54
Submitted on: Mar 18, 2015
|
Accepted on: Apr 20, 2015
|
Published on: Jun 5, 2015
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
atherosclerosis,
adhesion molecules,
cardiovascular disease,
interleukins,
inflammation,
oxidative stress,
statins
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Internal medicine, other,
Surgery,
Surgery, other,
Anaesthesiology,
Emergency medicine and intensive-care medicine

© 2015 Costas Psarros, Evangelos K. Economou, Michael Koutsilieris, Charalambos Antoniades, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 1 (2015): Issue 2 (April 2015)Next article